FINWIRES · TerminalLIVE
FINWIRES

研究报告提醒:CFRA将诺福克南方公司(Norfolk Southern Corp.)的评级从“买入”下调至“持有”,目标价为320美元。

By

-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:我们维持320美元的目标价,因为该股目前的交易价格与联合太平洋公司(UNP 271 ****)的收购价格相符。我们采用23.3倍的预期市盈率,基于2027年每股收益13.72美元的预期,高于五年平均水平17.7倍,这主要归因于并购溢价。NSC公布的第一季度调整后铁路运营收入为30亿美元,同比增长0.2%。该公司调整后的息税前利润率为31.3%,较上年同期下降80个基点,原因是通胀不利因素和燃油价格上涨部分抵消了生产率的提升。本季度的一大亮点是盈利大幅超出预期,调整后每股收益为2.65美元,高于市场普遍预期的2.51美元。 2026 年 1 月 16 日,美国地面运输委员会以申请材料不完整为由驳回了 UNP/NSC 的合并申请,将预计完成时间推迟至 2027 年中后期。华盛顿分析公司已将批准概率从 80% 下调至 70%,反映出监管审查力度加大。

Related Articles

Insider Trading

Lifestance Health Group Insider Sold Shares Worth $492,400, According to a Recent SEC Filing

Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml

$LFST
Australia

Celestica Q1 Adjusted Earnings, Revenue Rise; Q2 Guidance Set

Celestica (CLS) reported Q1 adjusted earnings late Monday of $2.16 per diluted share, up from $1.20 a year earlier.Analysts polled by FactSet expected $2.07.Revenue for the three months ended March 31 was $4.05 billion, up from $2.65 billion a year earlier.Analysts surveyed by FactSet expected $4.04 billion.For Q2, the company expects adjusted EPS of $2.14 to $2.34 on revenue of $4.15 billion to $4.45 billion. Analysts expect EPS of $2.13 on revenue of $4.17 billion.The company now expects 2026 adjusted EPS of $10.15 on revenue of $19 billion, revised from $8.75 and $17 billion, respectively, expected earlier. Analysts expect EPS of $8.93 on revenue of $17.34 billion.

$CLS
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Ameriprise Financial, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.

$AMP